Literature DB >> 29167171

Advances in our understanding of the pathogenesis of hemolytic uremic syndromes.

E E Bowen1, R J Coward1.   

Abstract

Hemolytic uremic syndrome (HUS) is major global health care issue as it is the leading cause of acute kidney injury in children. It is a triad of acute kidney injury, microangiopathic hemolytic anemia, and thrombocytopenia. In recent years, major advances in our understanding of complement-driven inherited rare forms of HUS have been achieved. However, in children 90% of cases of HUS are associated with a Shiga toxin-producing enteric pathogen. The precise pathological mechanisms in this setting are yet to be elucidated. The purpose of this review is to discuss advances in our understanding of the pathophysiology underlying HUS and identify the key questions yet to be answered by the scientific community.

Entities:  

Keywords:  complement; hemolytic uremic syndrome; thrombotic microangiopathy

Mesh:

Substances:

Year:  2017        PMID: 29167171      PMCID: PMC5899223          DOI: 10.1152/ajprenal.00376.2017

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  50 in total

Review 1.  Shiga toxins--from cell biology to biomedical applications.

Authors:  Ludger Johannes; Winfried Römer
Journal:  Nat Rev Microbiol       Date:  2009-12-21       Impact factor: 60.633

2.  Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.

Authors:  Ida Arvidsson; Anne-Lie Ståhl; Minola Manea Hedström; Ann-Charlotte Kristoffersson; Christian Rylander; Julia S Westman; Jill R Storry; Martin L Olsson; Diana Karpman
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

Review 3.  Complement factor H related proteins (CFHRs).

Authors:  Christine Skerka; Qian Chen; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Mol Immunol       Date:  2013-07-03       Impact factor: 4.407

Review 4.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

5.  Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function.

Authors:  Jing Jin; Karen Sison; Chengjin Li; Ruijun Tian; Monika Wnuk; Hoon-Ki Sung; Marie Jeansson; Cunjie Zhang; Monika Tucholska; Nina Jones; Dontscho Kerjaschki; Masabumi Shibuya; I George Fantus; Andras Nagy; Hans-Peter Gerber; Napoleone Ferrara; Tony Pawson; Susan E Quaggin
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

6.  Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome.

Authors:  F Proulx; E Wagner; B Toledano; H Decaluwe; E G Seidman; G-E Rivard
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 7.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

Review 8.  Comparative functional evolution of human and mouse CR1 and CR2.

Authors:  Amanda C Jacobson; John H Weis
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  VEGF regulates local inhibitory complement proteins in the eye and kidney.

Authors:  Lindsay S Keir; Rachel Firth; Lyndsey Aponik; Daniel Feitelberg; Susumu Sakimoto; Edith Aguilar; Gavin I Welsh; Anna Richards; Yoshihiko Usui; Simon C Satchell; Valeryia Kuzmuk; Richard J Coward; Jonathan Goult; Katherine R Bull; Ruchi Sharma; Kapil Bharti; Peter D Westenskow; Iacovos P Michael; Moin A Saleem; Martin Friedlander
Journal:  J Clin Invest       Date:  2016-12-05       Impact factor: 14.808

View more
  6 in total

1.  Role of the kidneys in the redistribution of heme-derived iron during neonatal hemolysis in mice.

Authors:  Aleksandra Bednarz; Paweł Lipiński; Rafał R Starzyński; Mateusz Tomczyk; Witold Nowak; Olga Mucha; Mateusz Ogórek; Olga Pierzchała; Aneta Jończy; Robert Staroń; Julia Śmierzchalska; Zenon Rajfur; Zbigniew Baster; Alicja Józkowicz; Małgorzata Lenartowicz
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

2.  Primary Human Renal Proximal Tubular Epithelial Cells (pHRPTEpiCs): Shiga Toxin (Stx) Glycosphingolipid Receptors, Stx Susceptibility, and Interaction with Membrane Microdomains.

Authors:  Johanna Detzner; Anna-Lena Klein; Gottfried Pohlentz; Elisabeth Krojnewski; Hans-Ulrich Humpf; Alexander Mellmann; Helge Karch; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2021-07-28       Impact factor: 4.546

Review 3.  Biofilms in the Food Industry: Health Aspects and Control Methods.

Authors:  Serena Galié; Coral García-Gutiérrez; Elisa M Miguélez; Claudio J Villar; Felipe Lombó
Journal:  Front Microbiol       Date:  2018-05-07       Impact factor: 5.640

Review 4.  Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome.

Authors:  Johanna Detzner; Gottfried Pohlentz; Johannes Müthing
Journal:  Toxins (Basel)       Date:  2020-06-04       Impact factor: 4.546

Review 5.  Combined liver-kidney transplantation for rare diseases.

Authors:  Mladen Knotek; Rafaela Novak; Alemka Jaklin-Kekez; Anna Mrzljak
Journal:  World J Hepatol       Date:  2020-10-27

Review 6.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.